Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sunshine Biopharma Inc. - Common stock
(NQ:
SBFM
)
0.3378
-0.0922 (-21.44%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sunshine Biopharma Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
These stocks are moving in today's session
↗
October 09, 2026
Via
Chartmill
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
October 09, 2026
$6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Top stock movements in today's session.
↗
October 08, 2026
Via
Chartmill
These stocks are making the most noise in today's session.
↗
October 08, 2026
Via
Chartmill
On Thursday, there are stocks with unusual volume. Let's take a look.
↗
October 08, 2026
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
October 08, 2026
Via
Chartmill
Traders are paying attention to the gapping stocks in Thursday's session.
↗
October 08, 2026
Via
Chartmill
Thursday's pre-market session: top gainers and losers
↗
October 08, 2026
Via
Chartmill
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
October 08, 2026
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
October 07, 2026
Via
Chartmill
Curious about the most active stocks on Wednesday?
↗
October 07, 2026
Via
Chartmill
What's going on in today's session
↗
October 07, 2026
Via
Chartmill
Monday's session: top gainers and losers
↗
October 05, 2026
Via
Chartmill
Keep an eye on the top gainers and losers in Monday's session.
↗
October 05, 2026
Via
Chartmill
Monday's session: gap up and gap down stocks
↗
October 05, 2026
Via
Chartmill
Discover the top movers in Monday's pre-market session.
↗
October 05, 2026
Via
Chartmill
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
September 24, 2026
Launch introduces ondansetron 4 mg and 8 mg tablets for nausea and vomiting associated with chemotherapy, radiation therapy and surgery Global ondansetron market projected to reach $2.98 billion by...
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
September 16, 2026
Nanomolar potency against PLpro with broad-spectrum SARS-CoV-2 variants activity Significant dose-dependent suppression of pulmonary viral replication in vivo Strong oral bioavailability and...
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
August 31, 2026
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology
From
MarketNewsUpdates.com
Via
GlobeNewswire
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
August 26, 2026
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market
August 19, 2026
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market
August 07, 2026
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval
August 04, 2026
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting
July 28, 2026
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
July 20, 2026
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
June 25, 2026
From
Sunshine Biopharma Inc.
Via
ACCESS Newswire
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
June 01, 2026
Via
ACCESS Newswire
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
May 29, 2026
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.